m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program

Area of Science:

• Oncology
• Pharmacology
• Clinical Drug Development

Background:

• Amsacrine (m-AMSA) is an investigational drug evaluated by the National Cancer Institute Drug Development Program.
• Preclinical and early-phase clinical data indicate moderate toxicity and antitumor effects.

Purpose of the Study:

• To review existing preclinical and Phase I clinical data for amsacrine (m-AMSA).
• To summarize ongoing Phase II studies and propose future research directions.
• To facilitate a structured evaluation of amsacrine's therapeutic potential.

Main Methods:

• Review of preclinical research findings.
• Analysis of Phase I clinical trial results.
• Compilation and assessment of ongoing Phase II study data.

Main Results:

• Amsacrine (m-AMSA) exhibits moderate, tolerable toxicity.
• Demonstrated tumor activity in acute leukemia and breast cancer models.
• Numerous Phase II studies are completed or underway, with Phase III trials imminent.

Conclusions:

• Amsacrine (m-AMSA) presents a tolerable toxicity profile with demonstrated efficacy in specific cancers.
• Further structured clinical trials are necessary to fully ascertain its value.
• Recommendations are provided for future studies to ensure efficient assessment.